We need the help of ROS1ders to make it happen.
From 1 February 2020, Australian who have ROS1+ lung cancer may be able to purchase the medication through self funding as well since the Therapeutic Goods Administration has made a recommendation to the Australian Government for this drug to go on market. Unfortunately, the Australian private health insurance industry does not pay for the cost of medicines. This means that most Australians would not realistically be able to afford the cost of Entrectinib without Government subsidy.
An application for Government subsidy under the Pharmaceutical Benefits Scheme (PBS) has been made. The Pharmaceutical Benefits Advisory Committee will make a recommendation to the Australian Government, on the basis of scientific evidence and community experiences, as to whether the Government should subsidise the cost of Entrectinib.
We are calling on the international ROS1der community for support! If you are a patient, family, friend or interested community member, you can help us by simply emailing the Pharmaceutical Benefits Advisory Committee (PBAC) at CommentsPBAC@health.gov.au before 12 February 2020.
What to include in your email:
- Explain why you support this application to the PBAC for a positive recommendation to list Entrectinib on the Pharmaceutical Benefits Scheme (PBS)
- Share you story with ROS1 and Entrectnib (or targeted therapy in general)
- Explain how Entrectinib has made a difference in your life and those around you
- If you have not taken Entrectinib, explain what difference having access to Entrectinib would have made for you and/or your family
Whether it’s your personal story or the story of someone close to you, every story you share about Entrectinib will help give future ROS1+ lung cancer patients in Australia another possible treatment and immeasurable hope.
Thank you for your help!
Australian ROS1der and patient research advocate